AI assistant
Iterum Therapeutics plc — Director's Dealing 2018
May 30, 2018
34796_dirs_2018-05-30_0680f775-6905-46c0-a659-5a77819fe566.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-05-30
Reporting Person: Malik Shahzad (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-05-30 | Ordinary Shares | C | 13921 | — | Acquired | 13921 | Indirect |
| 2018-05-30 | Ordinary Shares | C | 7771 | — | Acquired | 21692 | Indirect |
| 2018-05-30 | Ordinary Shares | P | 8144 | $13.00 | Acquired | 29836 | Indirect |
| 2018-05-30 | Ordinary Shares | C | 391147 | — | Acquired | 391147 | Indirect |
| 2018-05-30 | Ordinary Shares | C | 218338 | — | Acquired | 609485 | Indirect |
| 2018-05-30 | Ordinary Shares | P | 228840 | $13.00 | Acquired | 838325 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-05-30 | Series B-1 Preferred Shares | $ | C | 13921 | Disposed | Ordinary Shares (13921) | Indirect | |
| 2018-05-30 | Series B-2 Preferred Shares | $ | C | 7771 | Disposed | Ordinary Shares (7771) | Indirect | |
| 2018-05-30 | Series B-1 Preferred Shares | $ | C | 391147 | Disposed | Ordinary Shares (391147) | Indirect | |
| 2018-05-30 | Series B-2 Preferred Shares | $ | C | 218338 | Disposed | Ordinary Shares (218338) | Indirect |
Footnotes
F1: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
F2: Securities are held by Advent Life Sciences LLP ("Advent"). The Reporting Person is a general partner of Advent, and disclaims beneficial ownership of the shares held by Advent except to the extent of his indirect pecuniary interest therein.
F3: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
F4: Securities are held by Advent Life Sciences Fund II LP. Advent is the general partner of Advent Life Sciences Fund II LP and the Reporting Person is a general partner of Advent. The Reporting Person disclaims beneficial ownership of the shares held by Advent Life Sciences Fund II LP except to the extent of his indirect pecuniary interest therein.
F5: Not applicable.